FINWIRES · TerminalLIVE
FINWIRES

SHE:002773

11 stories mentioning SHE:002773Updated 9d ago

Every FINWIRES story that references SHE:002773, newest first.

What's the latest news on SHE:002773?

Asia

Kanghong Subsidiary Gets China Nod for Additional Indication for Ophthalmic Injection in Infants

Chengdu Kanghong Pharmaceutical (SHE:002773) subsidiary Chengdu Kanghong Biotechnology obtained a drug registration certificate from China's National Medical Products Administration for an additional indication of its Conbercept ophthalmic injection, according to a Friday filing with the Shenzhen Stock Exchange.The permit is for the indication of retinopathy in preterm infants. The drug is already indicated for neovascular or wet age-related macular degeneration and visual impairment caused by choroidal neovascularization, the filing said.

SHE:002773
Asia

Kanghong Pharmaceutical Invests 50 Million Yuan in Structured Deposit

Chengdu Kanghong Pharmaceutical (SHE:002773) purchased a 50-million-yuan structured deposit from Bank of Chengdu, as part of its 3.8-billion-yuan wealth management program.The 92-day product offers a guaranteed minimum yield of 1.00% and a maximum expected yield of 1.80%, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 8% higher Friday.

SHE:002773
Asia

Kanghong Pharma Wins Bid in China National Drug Procurement

Chengdu Kanghong Pharmaceutical (SHE:002773) was named a proposed winner in China's 12th batch of national centralized drug volume-based procurement for perampanel tablets.The drug treats partial-onset and primary generalized tonic-clonic seizures in adults and children, according to a Monday filing with the Shenzhen bourse.Under the program, procurement runs through December 2029.Shares of the pharmaceutical company were up 1% in recent trade.

SHE:002773
Asia

Kanghong Pharma's Unit Gets Nod to Trial KHN921 Injection

Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Hongji Biotechnology, obtained approval from China's National Medical Products Administration for the clinical trial of KHN921 injection, according to a Shenzhen bourse filing on Friday.The drug will be tested as a treatment of hypertrophic cardiomyopathy caused by MYBPC3 mutations.

SHE:002773
Asia

Chengdu Kanghong Pharmaceutical, Unit Invest 252 Million Yuan in Structured Deposits

Chengdu Kanghong Pharmaceutical (SHE:002773) and subsidiary Kanghong Biotech have purchased structured deposit wealth management products totaling 252 million yuan, according to a Monday filing with the Shenzhen bourse.The company invested 100 million yuan in a China Merchants Bank 92-day structured deposit product, while Kanghong Biotech invested 152 million yuan in a CITIC Bank 198-day structured deposit product.Shares of the pharmaceutical company closed 2% lower Tuesday.

SHE:002773
Asia

Chengdu Kanghong Pharmaceutical Buys 1.7 Billion Yuan of Structured Deposit Products

Chengdu Kanghong Pharmaceutical (SHE:002773) purchased 1.7 billion yuan of structured deposit products from Bank of China (HKG:3988, SHA:601988).The deposit product has a 204-day term expiring Dec. 30, according to a Wednesday bourse filing in Shenzhen.

HKG:3988SHA:601988SHE:002773
Asia

Kanghong Pharmaceutical Unit Buys Wealth Management Product for 1.70 Billion Yuan

Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Kanghong Biotech, purchased a wealth management product for 1.70 billion yuan, according to a Shenzhen bourse filing on Wednesday.The wealth management product is a renminbi-denominated structured deposit from Bank of China (SHA:601988, HKG:3988), with a term of 204 days.The product's annualized return is 0.60% if its linked indicator reaches or exceeds the observation level, but the annualized return would be at 1.75% if the linked indicated remains below the observation level throughout the observation period.

HKG:3988SHA:601988SHE:002773
Asia

Chengdu Kanghong Pharmaceutical Purchases 200 Million Yuan of Structured Deposit Products

Chengdu Kanghong Pharmaceutical (SHE:002773) purchased 200 million yuan of structured deposit products from Bank of China (HKG:3988, SHA:601988), according to a Tuesday filing with the Shenzhen bourse.The wealth management product has a term of 207 days, expiring on Dec. 25, 2026.

HKG:3988SHA:601988SHE:002773
Asia

Kanghong Pharma Gets China Approval for Epilepsy Drug

Chengdu Kanghong Pharmaceutical (SHE:002773) obtained drug registration from China's medical products regulator for 2- and 4-milligram dosages of perapanel tablets.The drug is used to treat partial-onset and primary generalized tonic-clonic seizures, according to a Friday fling with the Shenzhen bourse.Shares of the pharmaceutical company were down 1% in recent trade.

SHE:002773
Asia

Kanghong Pharmaceutical's Unit Gets Nod to Trial KH812 Injection

Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Kanghong Biotechnology, received approval from China's National Medical Products Administration for the clinical trial of KH812 injection, according to a Shenzhen bourse filing on Wednesday.The drug will be tested as a treatment for neovascular (wet) age-related macular degeneration.

SHE:002773
Asia

Kanghong Pharmaceutical's Unit Secures US FDA Nod for Heart Disease Gene Therapy

Chengdu Kanghong Pharmaceutical's (SHE:002773) unit, Chengdu Hongji Biotechnology, said the U.S. Food and Drug Administration authorized the clinical trials of KHN921 injection in the U.S., according to a Shenzhen bourse filing on Monday.The drug will be tested as a treatment for hypertrophic cardiomyopathy.The pharmaceutical company's shares rose 2% during the afternoon trade.

SHE:002773

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:002773 in your portfolio
WheelAI
WheelAI
Analyze SHE:002773 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:002773